Semaglutide guidelines in the UK: the clinical rules that shape your treatment

You've seen Wegovy mentioned everywhere, here's what the actual rules say it's for

Semaglutide for weight management (Wegovy) holds a UK licence for adults who meet specific BMI criteria alongside a commitment to dietary and lifestyle changes. The licence itself, issued by the MHRA, sets the outer boundary: a BMI of 30 or above, or 27–29.9 where there is at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. That is the licensed population. Whether you personally meet it is a clinical judgement made by a prescriber, not an automatic yes based on a number on a scale.

NICE went further with its 2023 appraisal of Wegovy (TA875), setting tighter conditions specifically for NHS supply. Under those guidelines, semaglutide is recommended only when prescribed within a specialist weight management service, and only for a maximum of two years. The BMI threshold under TA875 is 35 or above with at least one weight-related comorbidity, or 30–34.9 where specific referral criteria are met. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds the thresholds are each 2.5 kg/m² lower. You can read the full NICE appraisal of semaglutide (TA875) to see the committee's reasoning in detail.

For private treatment the licensed eligibility criteria apply rather than the narrower NHS ones, but a responsible prescriber will still apply the same clinical rigour. If you want to understand what that looks like in practice, our semaglutide guide walks through the full picture of how the medicine works and what clinicians consider at each stage, while the prescribing guidelines for Wegovy page covers what clinicians look for at each stage.

What the dosing guidelines actually require, and why the pace matters

The dosing schedule for Wegovy is not arbitrary. The guidelines prescribe a slow escalation because GI side effects (nausea, vomiting, loose stools) are most pronounced when the dose rises, and a stepped approach gives most people's digestive systems time to adjust. Treatment starts at 0.25mg weekly. After approximately four weeks the prescriber typically moves to 0.5mg, then 1.0mg, then 1.7mg, then the standard 2.4mg maintenance dose, each step roughly four weeks apart.

The MHRA approved a higher 7.2mg maintenance dose in January 2026 and a dedicated single-dose 7.2mg pen in April 2026, available for adults with a BMI of 30 or above. That pen uses an auto-dosing mechanism with a built-in covered needle and locks after use. Even with the expanded dose ceiling, the titration principle holds: starting dose remains 0.25mg and the prescriber determines when and whether each increase is appropriate. Self-titrating based on what worked for a friend is not covered by any guideline, and clinically it is not safe.

NICE guidance also specifies a review point: if a patient has not achieved at least 5% weight loss after six months on their maintenance dose, continuing is assessed against expected benefit. That clinical checkpoint is part of the guidelines, not a discretionary add-on. Our Wegovy user guide explains what to expect at each stage in plain terms.

The safety guidelines your prescriber follows, and what you can do

Wegovy carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring because it is a relatively new medicine. That monitoring generates real-world safety data and feeds back into updated guidance, which is how the system is meant to work.

The prescribing guidelines require clinicians to counsel patients on recognised side effects before starting treatment. On the serious end, the MHRA Drug Safety Update programme covers acute pancreatitis as an infrequent but known risk: severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems, dehydration from persistent vomiting, and allergic reactions are also flagged in the safety framework.

Patients can play an active part in this. Reporting any suspected side effect through the Yellow Card scheme at yellowcard.mhra.gov.uk contributes to the MHRA's ongoing assessment. Semaglutide is not recommended during pregnancy, while breastfeeding, or when trying to conceive; it is not licensed for anyone under 18. These are not caveats buried in small print, they are part of the prescribing guidelines that every legitimate clinician follows.

Surgery also requires specific attention. NHS guidance states that anyone taking a GLP-1 medicine should inform their surgical and anaesthetic team ahead of any procedure. The anaesthesia guidelines for Wegovy page covers this in full if it applies to you.

Private treatment and how guidelines apply outside the NHS

The clinical guidelines do not change depending on whether you access semaglutide privately or through the NHS. What changes is the route, the waiting time, and the cost. NHS access follows NICE TA875 thresholds and requires a specialist service; the waiting lists in many areas are long. Private treatment through a regulated pharmacy such as ours at nume operates under the same MHRA licence and the same prescribing standards, but without NHS referral criteria or service-level delays.

Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not automated processing. Photo ID verification, live weight checks and GP notification are part of every new patient's pathway. Some patients also ask about combining treatments, and our page on BPC-157 and semaglutide covers what the evidence and guidelines say about using these alongside each other. If you'd like to understand the cost side of private treatment, our Wegovy cost page sets out what's included in a private prescription service and what market prices typically look like.

If you think semaglutide may be appropriate for you, the right next step is a clinical conversation rather than a search page. Speak to our prescribers through a free consultation and they will give you an honest assessment based on the same guidelines described here.